Literature DB >> 1745617

Complications associated with immunosuppressive therapy and their management.

D I Min1, A P Monaco.   

Abstract

Besides general complications of immunosuppression such as increased susceptibility to opportunistic infections or malignancy, individual immunosuppressive agents are associated with specific side effects. Nephrotoxicity is the major side effect of cyclosporine (CsA). Various attempts have been made to minimize this toxicity, such as monitoring drug blood levels, modifying the protocol, and coadministering other agents. Other side effects caused by CsA are hepatotoxicity, hyperkalemia, hypertension, tremor, gum overgrowth, and hirsutism. Azathioprine (AZA) causes dose-related bone marrow suppression, commonly leading to leukopenia. Careful monitoring of complete blood cell count and dosage adjustment according to white blood cell count are usually adequate to prevent serious leukopenia. The side effects of corticosteroids are numerous and include slow wound healing and de novo insulin-dependent diabetes mellitus. Many complications are dose related, and with low dosage or discontinuation of steroids, their frequency rapidly decreases. Antilymphoblast and antithymocyte globulins (P-ALG) are foreign antibodies and may cause allergic-type reactions such as fever, chill, and hypotension. The initial side effect of monoclonal antibody (muromonab-CD3, OKT3) is similar to that of P-ALG. It includes high fever, shaking chills, headache, rigors, and hypotension. To prevent it, acetaminophen, an antihistamine, and a steroid usually are administered before injection. Because this agent is also associated with high frequency of pulmonary edema, it should not be given to any patient who has more than 3% body weight gain during the week prior to therapy. In rare case, it causes aseptic meningitis or encephalopathy, which is manifested by fever, severe headache, and seizure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1745617

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  15 in total

1.  A neurologist's approach to the immunosuppressed patient.

Authors:  C Dougan; I Ormerod
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

2.  Should ileoanal pouch surgery be staged for patients with mucosal ulcerative colitis on immunosuppressives?

Authors:  Oded Zmora; Marat Khaikin; Turab Pishori; Alon Pikarsky; Adam Dinnewitzer; Eric G Weiss; Juan J Nogueras; Steven D Wexner
Journal:  Int J Colorectal Dis       Date:  2006-08-24       Impact factor: 2.571

Review 3.  Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.

Authors:  M I Wilde; K L Goa
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

4.  Effects of long-term administration of low-dose FTY720 on survival of murine cardiac allograft.

Authors:  Qi Cheng; Dan Li; Huifang Liang; Hongqiang Yang; Dou Lei; Dan Gao; Xin Long; Yifa Chen; Peng Zhu; Xiaoping Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-04-20

5.  Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome.

Authors:  Xinsheng Zhang; Konstantin Alekseev; Kwonil Jung; Anastasia Vlasova; Nagesh Hadya; Linda J Saif
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

6.  Amoxicillin-induced aseptic meningoencephalitis.

Authors:  Radi Shahien; Vetaly Vieksler; Abdalla Bowirrat
Journal:  Int J Gen Med       Date:  2010-07-21

7.  Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial.

Authors:  Anna Teresa Mazzeo; Gretchen M Brophy; Charlotte B Gilman; Oscar Luís Alves; Jaime R Robles; Ronald L Hayes; John T Povlishock; M Ross Bullock
Journal:  J Neurotrauma       Date:  2009-12       Impact factor: 5.269

Review 8.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

Review 9.  Novel delivery of pancreatic islet cells to treat insulin-dependent diabetes mellitus.

Authors:  T Maki; C J Mullon; B A Solomon; A P Monaco
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

Review 10.  Engineering universal cells that evade immune detection.

Authors:  Robert Lanza; David W Russell; Andras Nagy
Journal:  Nat Rev Immunol       Date:  2019-08-15       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.